Drugs / RO7123520
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03001219 | Dec 2016 → Nov 2018 | rheumatoid arthritis | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7123520 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03001219 ↗ |
| Route | Intravenous | “Participants will receive intravenous infusion of RO7123520.” NCT03001219 ↗ |